ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 838

Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis?

Juliette Yedimenko1, Yuxuan Jin 2, Alexis Ogdie 3, Jessica Walsh 4, Jose Scher 5, Soumya Reddy 6 and M. Elaine Husni 1, 1Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 2Quantitative Health Science, Cleveland Clinic, Cleveland, OH, 3Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 4Division of Rheumatology, University of Utah, Salt Lake City, UT, 5Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, 6Division of Rheumatology, New York University School of Medicine, New York, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: patient-reported outcome measures, PROMIS and Disease Activity, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S076: Patient Outcomes, Preferences, & Attitudes I: Patient Reported Outcomes (833–838)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Patient-reported outcomes (PROs) are an important part of clinical decision making and are frequently used in combination with objective measures of disease activity and physicians’ clinical assessment to help guide treatment decisions. Discrepancies between PROs and clinical measures of disease activity can lead to over-treated or under-treated disease and patient dissatisfaction. We sought to examine the correlation between minimal disease activity (MDA) with PROs as measured by the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health (GH) questionnaire, and assess the effect of demographics, psoriatic arthritis related comorbidities, and number of comorbidities on PROMIS GH and MDA status.

Methods: A cross-sectional study was performed within Psoriatic Arthritis Research Consortium (PARC), a cohort of adult psoriatic arthritis patients meeting CASPAR criteria enrolled between 2016-2019. PARC is a longitudinal observational cohort study conducted at four institutions in the United States. The mean differences of PROMIS Physical, Mental and Fatigue T-scores between patients in MDA compared to those not in MDA were compared using the two sample t-tests. Correlations between MDA scores (0-7 criteria met) and PROMIS Physical, Mental and Fatigue T-scores were calculated using Spearman rank correlation. Higher T-scores on PROMIS measures mean ‘more’ of that concept for PROMIS Physical and Mental domains. Logistic regression model was used to evaluate contribution of additional covariates on MDA, including age, gender, hypertension, dyslipidemia, BMI, diabetes, smoking and number of comorbidities (Table 2). The odds ratios and 95% confidence intervals were presented. Multiple imputation was performed to impute missing data points. Data analysis was performed in SAS software (Version 9.4; Cary, NC).

Results: 235 patients (50% female, mean age 51±13.9) were included. 129 were in MDA and 106 were not in MDA. Patients in MDA had significantly higher PROMIS Physical, Mental and improved Fatigue T-scores compared to non-MDA patients (Table 1; p< 0.001). There was a positive correlation between MDA scores and PROMIS scores in Physical and Mental domains; correlation was strongest for PROMIS Physical T-score (Figure 1; r=0.65, p< 0.001). There was a moderate correlation between MDA and PROMIS Fatigue T-score (Figure 1; r=-0.51, p< 0.001). In the univariate analysis, there was a statistically significant association between hypertension and number of comorbidities with MDA status (Table 2). However, this effect was not observed in the multivariate analysis.

Conclusion: Achieving MDA was associated with a positive effect on patients’ physical, mental and fatigue domains, irrespective of their demographics or PsA comorbidities. However, patients with a greater number of comorbidities were less likely to be in MDA. In this study, the PROMIS Physical domain had a higher correlation with MDA scores compared to the Mental domain and PROMIS Fatigue. PROMIS measures may be a useful tool in assessing disease activity from the patient’s perspective.

Acknowledgement: Funded by NIH/NIAMS R01 AR072363

Table 1. Comparison of PROMIS domains between MDA and non-MDA patients

Figure 1. Scatterplot of MDA and PROMIS Physical, Mental and Fatigue Domains

Table 2. Univariate association between MDA and different covariates


Disclosure: J. Yedimenko, None; Y. Jin, None; A. Ogdie, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie, BMS, Eli Lilly, Novartis, Pfizer, Takeda, 5, Amgen, 2, 4, 5, 8, Amgen to Forward National Databank, 2, BMS, 5, Bristol-Myers Squibb, 5, Celgene, 4, 5, 8, Corrona, 5, CORRONA, 5, From Noavrtis to husband, 7, Lilly, 5, Lily, 5, Novartis, 2, 5, 7, Novartis to UPenn, 2, Novartis, Pfizer, 2, Pfizer, 2, 5, Pfizer Inc, 2, 5, Pfizer to UPenn, 2; J. Walsh, AbbVie, 2, 5, ABBVIE, NOVARTIS, LILLY, AMGEN, UCB, 5, Amgen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, PFIZER, ABBVIE, 2, UCB, 5; J. Scher, Amgen, 5, Bristol-Myers Squibb, 5, Janssen, 5, Novartis, 2, 5, Pfizer, 2, UCB, 5; S. Reddy, Novartis, 5, Pfizer, 8, UCB, Amgen, 5, Abbvie, 5; M. Husni, Abbvie, 5, AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, UCB, 5, Abbvie, Amgen, Janssen, Novartis, Lilly, Regeneron, Pfizer and UCB, 5, Bristol-Myers Squibb, 5, Eli Lilly, 5, Genentech, 5, Janssen, 5, Janssen Research & Development, LLC, 2, 3, Novartis, 5, PASE questionnaires, 7, Pfizer, 5, Sanofi-Genzyme, 5, UCB, 5.

To cite this abstract in AMA style:

Yedimenko J, Jin Y, Ogdie A, Walsh J, Scher J, Reddy S, Husni M. Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/are-promis-measures-associated-with-minimal-disease-activity-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-promis-measures-associated-with-minimal-disease-activity-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology